Lexicon Pharmaceuticals (LXRX) EBT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 103.79% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 24.03% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 41.79% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 38.36% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -38.56% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 64.03% |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | 14.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.19% |
| Mar 31, 2026 | 57.08% |
| Dec 31, 2025 | 18.73% |
| Sep 30, 2025 | 16.12% |
| Jun 30, 2025 | 27.18% |
| Mar 31, 2025 | -5.37% |
| Dec 31, 2024 | -12.61% |
| Sep 30, 2024 | -43.43% |
| Jun 30, 2024 | -46.96% |
| Mar 31, 2024 | -33.79% |
| Dec 31, 2023 | -111.73% |
| Sep 30, 2023 | -38.35% |
| Jun 30, 2023 | 13.08% |
| Mar 31, 2023 | 21.19% |
| Dec 31, 2022 | 15.08% |
| Sep 30, 2022 | -28.27% |
| Jun 30, 2022 | -1.62% |
| Mar 31, 2022 | -1.42% |
| Dec 31, 2021 | -15.16% |
| Sep 30, 2021 | 5.48% |